MediWound’s NexoBrid® and EscharEx® to be Highlighted in Multiple Presentations at the Symposium on Advanced Wound Care S...
March 30 2017 - 9:00AM
MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical
company bringing innovative therapies to address unmet needs in
severe burn and wound management, announces that seven
presentations highlighting the positive clinical results from using
NexoBrid® as an enzymatic debridement for severe burns and EscharEx
for the debridement of chronic wounds will be presented during the
Symposium on Advanced Wound Care Spring/Wound Healing Society
Meeting (SAWC Spring), taking place April 5-9, 2017 in San Diego,
California.
“We are delighted with the depth and breadth of
data to be presented at this year’s SAWC Spring in support of the
effectiveness of EscharEx and NexoBrid in wound management and burn
care, respectively. We are pleased to have the positive data
from our EscharEx Phase 2 clinical trial presented as it
demonstrates the important role this product can play in the
treatment of chronic wounds. Debridement is a critical first step
to facilitate wound management and is complementary to the large
number of existing wound healing products, which require a clean
wound bed in order to heal the wound. It is thought that EscharEx
could allow more patients to benefit from advanced wound healing
and skin substitute products, which generally are not applied on
wounds covered with eschar. We believe EscharEx can fill the
long-standing unmet medical need for an effective and rapid
nonsurgical debridement treatment for chronic wounds,” said Gal
Cohen, President and Chief Executive Officer of MediWound.
“The SAWC Spring meeting is a particularly good
program as it brings together the entire interdisciplinary wound
care team to learn more about advances in the field that will
facilitate improved patient outcomes. We look forward to
sharing our compelling data with these clinicians and to expanding
the awareness of our proteolytic enzyme technologies as effective
debridement treatments in severe burns and chronic wounds,” added
Mr. Cohen.
The following data highlighting NexoBrid and
EscharEx will be presented during the SAWC Spring
meeting:
Title: |
|
“Rapid Enzymatic Debridement of Chronic Wounds: Results of
a Multi-Center Phase II Trial” |
Poster: |
|
Poster Presentation CR-070 |
Presenter: |
|
Y.
Shoham, M.D., Plastic and Reconstructive Surgeon, Soroka University
Medical Center, Beer Sheva, Israel |
|
|
|
Title: |
|
“Review of Pediatric Clinical Experience with Rapid
Enzymatic Burn Debridement” |
Poster: |
|
Poster Presentation CR-071 |
Presenter: |
|
Y.
Shoham, M.D., Plastic and Reconstructive Surgeon, Soroka University
Medical Center, Beer Sheva, Israel |
|
|
|
Title: |
|
“Rapid Enzymatic Burn Debridement: Review of Seven Clinical
Studies” |
Poster: |
|
Poster presentation CR-072 |
Presenter: |
|
Y.
Shoham, M.D., Plastic and Reconstructive Surgeon, Soroka University
Medical Center, Beer Sheva, Israel |
|
|
|
Title: |
|
“Rapid Enzymatic Burn Debridement: Results of a
Multinational Randomized Controlled Trial” |
Poster: |
|
Poster presentation CR-073 |
Presenter: |
|
Y.
Shoham, MD, Plastic and Reconstructive Surgeon, Soroka University
Medical Center, Beer Sheva, Israel; |
|
|
|
Title: |
|
“Rapid Enzymatic Debridement of Chronic Wounds: Preliminary
Results” |
Poster: |
|
Poster presentation CR-063 |
Presenter: |
|
Y.
Shoham, M.D., Plastic and Reconstructive Surgeon, Soroka University
Medical Center, Beer Sheva, Israel |
|
|
|
Title: |
|
“The Use of Rapid Enzymatic Debridement in the 2015
Romanian burn Mass Casualty Incident: Ground Breaking
Experience” |
Report: |
|
Informational/Educational Report IR-042 |
Author: |
|
Y.
Shoham, M.D., Plastic and Reconstructive Surgeon, Soroka University
Medical Center, Beer Sheva, Israel |
|
|
|
Title: |
|
“Implementation of a Medical Training Program for the
Introduction of a New, Rapid Enzymatic Eschar Removal
Agent” |
Report: |
|
Informational/Educational Report IR-043 |
Author: |
|
Y.
Shoham, M.D., Plastic and Reconstructive Surgeon, Soroka University
Medical Center, Beer Sheva, Israel |
About SAWC Spring/Wound Healing Society
Meeting
The Symposium on Advanced Wound Care/Wound
Healing Society Meeting is the nation’s largest and most
well-respected interdisciplinary wound care program within the
clinical field. The Symposium on Advanced Wound Care Spring | Wound
Healing Society meeting (SAWC Spring | WHS) serves as a forum to
connect the entire wound care team — physicians, nurses, physical
therapists, researchers, scientists, podiatrists and dietitians —
with the foremost experts in wound care to improve patient outcomes
through education. No other wound care conference offers the level
of education, advanced state-of-the-art clinical reviews and
emerging research findings.
About MediWound Ltd.
MediWound is a fully-integrated
biopharmaceutical company focused on developing, manufacturing and
commercializing novel therapeutics based on its patented
proteolytic enzyme technology to address unmet needs in the fields
of severe burns, chronic and other hard-to-heal wounds. MediWound’s
first innovative biopharmaceutical product, NexoBrid®, received
marketing authorization from the European Medicines Agency as well
as the Israeli and Argentinian Ministries of Health, for removal of
dead or damaged tissue, known as eschar, in adults with deep
partial and full-thickness thermal burns and was launched in Europe
and Israel, with plans for a launch in Argentina.
NexoBrid® represents a new paradigm in burn care management,
and clinical trials have demonstrated, with statistical
significance, its ability to non-surgically and rapidly remove the
eschar earlier and, without harming viable tissues.
MediWound's second innovative product, EscharEx®
is a topical biological drug being developed for debridement of
chronic and other hard-to-heal wounds and is complementary to the
large number of existing wound healing products, which require a
clean wound bed in order to heal the wound. EscharEx® contains the
same proteolytic enzyme technology as NexoBrid®, and benefits from
the wealth of existing development data on NexoBrid®. In two
Phase 2 studies, EscharEx® has demonstrated safety and efficacy in
the debridement of chronic and other hard-to-heal wounds, within a
few daily applications. For more information, please
visit www.mediwound.com.
Cautionary Note Regarding
Forward-Looking StatementsThis release includes
forward-looking statements within the meaning of Section 27A of the
U.S. Securities Act of 1933, as amended, Section 21E of the US
Securities Exchange Act of 1934, as amended, and the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of
1995. Forward-looking statements are statements that are not
historical facts, such as statements regarding assumptions and
results related to the regulatory authorizations and launch
dates. In some cases, you can identify forward-looking
statements by terminology such as “believe,” “may,” “estimate,”
“continue,” “anticipate,” “intend,” “should,” “plan,” “expect,”
“predict,” “potential,” or the negative of these terms or other
similar expressions. Forward-looking statements are based on
MediWound’s current knowledge and its present beliefs and
expectations regarding possible future events and are subject to
risks, uncertainties and assumptions. Actual results and the timing
of events could differ materially from those anticipated in these
forward-looking statements as a result of several factors. In
particular, you should consider the risks discussed under the
heading “Risk Factors” in our annual report on Form 20-F for the
year ended December 31, 2016 and information contained in other
documents filed with or furnished to the Securities and Exchange
Commission. You should not rely upon forward-looking statements as
predictions of future events. Although we believe that the
expectations reflected in the forward-looking statements are
reasonable, we cannot guarantee that future results, levels of
activity, performance and events and circumstances reflected in the
forward-looking statements will be achieved or will occur. The
forward-looking statements made herein speak only as of the date of
this announcement and MediWound undertakes no obligation to update
publicly such forward-looking statements to reflect subsequent
events or circumstances, except as otherwise required by law.
Contacts: |
|
|
Anne
Marie Fields |
Sharon Malka |
|
|
Senior Vice President |
Chief
Financial and Operations Officer |
|
|
LHA |
MediWound |
|
|
212-838-3777 |
ir@mediwound.co.il |
|
|
afields@lhai.com |
MediWound (NASDAQ:MDWD)
Historical Stock Chart
From Mar 2024 to Apr 2024
MediWound (NASDAQ:MDWD)
Historical Stock Chart
From Apr 2023 to Apr 2024